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Anju Suhag, MD; Gabriele Saccone, MD; Vincenzo Berghella, MDreterm birth (PTB), deﬁned as birthOBJECTIVE: We sought to evaluate the efficacy of maintenance tocolysis with vaginal
progesterone compared to control (placebo or no treatment) in singleton gestations with
arrested preterm labor (PTL) in a metaanalysis of randomized controlled trials.
STUDYDESIGN: Searches were performed in MEDLINE, OVID, Scopus, ClinicalTrials.gov,
and the Cochrane Central Register of Controlled Trials with the use of a combination of
key words and text words related to “progesterone,” “tocolysis,” and “preterm labor”
from 1966 through November 2014. We included all randomized trials of singleton
gestations that had arrested PTL and then were randomized to maintenance tocolysis
treatment with either vaginal progesterone or control (either placebo or no treatment). All
published randomized studies on progesterone tocolysis were carefully reviewed.
Exclusion criteria included maintenance tocolysis in women with preterm premature
rupture of membrane, maintenance tocolysis with 17-alpha-hydroxyprogesterone cap-
roate, and maintenance tocolysis with oral progesterone. The summary measures were
reported as relative risks (RRs) with 95% confidence interval (CI). The primary outcome
was preterm birth (PTB) <37 weeks.
RESULTS: Five randomized trials, including 441 singleton gestations, were analyzed.
Women who received vaginal progesterone maintenance tocolysis for arrested PTL had a
significantly lower rate of PTB<37 weeks (42% vs 58%; RR, 0.71; 95% CI, 0.57e0.90;
3 trials, 298 women). Women who received vaginal progesterone had significantly longer
latency (mean difference 13.80 days; 95% CI, 3.97e23.63; 4 trials, 368 women), later
gestational age at delivery (mean difference 1.29 weeks; 95% CI, 0.43e2.15; 4 trials,
368 women), lower rate of recurrent PTL (24% vs 46%; RR, 0.51; 95% CI, 0.31e0.84;
2 trials, 122 women), and lower rate of neonatal sepsis (2% vs 7%; RR, 0.34; 95% CI,
0.12e0.98; 4 trials, 368 women).
CONCLUSION: Maintenance tocolysis with vaginal progesterone is associated with
prevention of PTB, significant prolongation of pregnancy, and lower neonatal sepsis.
However, given the frequent lack of blinding and the generally poor quality of the trials,
we do not currently suggest a change in clinical care of women with arrested PTL. WeP between 20 and 36 6/7 weeks, is
responsible for the majority of the
neonatal morbidity and mortality in the
United States,1-3 and 35% of all US health
care spending on infants.4 Globally, about
28% of the 4 million annual neonatal
deaths are directly attributable to PTB.5
Preterm labor (PTL) is the ﬁnal
pathway for about 50% of all PTB.
Tocolytic agents are drugs that can slow
or stop labor contractions in the attempt
to delay births preceded by PTL. Primary
tocolysis is deﬁned as tocolysis given on
initial presentation of women with PTL.
In most of these women, PTL stops, but
as their risk of PTB remains high, some
have advocated use of maintenance
tocolysis, ie, tocolysis after arrested PTL.
So far, no maintenance tocolytic agent
has been shown to be beneﬁcial in pre-
venting PTB.1 Recently, progesterone has
been used successfully for prevention of
PTB, in particular in asymptomatic
singleton gestations with either short
cervical length6,7 or with prior sponta-
neous PTB.8 The efﬁcacy of vaginal
progesterone in preventing PTB in
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suggest instead well-designed placebo-controlled randomized trials to confirm the
findings of our metaanalysis.
Key words: preterm birth, preterm labor, progesterone, tocolysisThe aim of this study was to evaluate
the efﬁcacy of maintenance tocolysis
with vaginal progesterone compared to
control (placebo or no treatment) in
singleton gestations with arrested PTL in
a metaanalysis of randomized trials.
Materials and methods
Study design
The research protocol was designed a
priori, deﬁningmethods for searching theOCTOBER 2015 Amliterature, including and examining arti-
cles, and extracting and analyzing data.
Searches were performed in MEDLINE,
OVID, Scopus, ClinicalTrials.gov, and the
Cochrane Central Register of Controlled
Trials with the use of a combination of
key words and text words “progesterone,”
“tocolysis,” and “preterm labor” from
1966 through November 2014. To locate
additional publications, we reviewed
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FIGURE 1
Flow diagram of studies
identified in systematic review
PPROM, preterm premature rupture of membrane; 17P, 17-
alpha-hydroxyprogesterone caproate.
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Systematic Reviews Obstetrics ajog.orgmeetings on PTB and tocolysis and bib-
liographies of identiﬁed studies and re-
views articles.No restrictions for language
or geographic location were applied.
We included randomized trials of
singleton gestations that had arrested PTL
and then were randomized to mainte-
nance tocolysis treatment with either
vaginal progesterone or control (either
placebo or no treatment). All published
randomized studies on progesterone
tocolysis were carefully reviewed. Exclu-
sion criteria included quasirandomized
trials (ie, trials in which allocation was480 American Journal of Obstetrics& Gynecologydone on the basis of a pseudorandom
sequence, eg, odd/even hospital number
or date of birth, alternation), mainte-
nance tocolysis in women with pre-
term premature rupture of membrane
(PPROM), maintenance tocolysis with
17-alpha-hydroxyprogesterone caproate
(17P), and maintenance tocolysis with
oral progesterone.
Before data extraction, the protocol
was registered with PROSPERO (regis-
tration number: CRD42014013706;
http://www.crd.york.ac.uk/PROSPERO/).9
The metaanalysis was reported following
the Preferred Reporting Item for Sys-
tematic Reviews and Meta-analyses
(PRISMA) statement.10
Data abstraction was completed by 3
independent investigators (G.S., A.S.,
V.B.). Each investigator independently
abstracted data from each study and
analyzed data separately. Differences
were reviewed, and further resolved by
common review of the entire data. All
authors were contacted for missing data.
The risk of bias in each included
study was assessed by using the criteria
outlined in the Cochrane Handbook
for Systematic Reviews of In-
terventions.11 Seven domains related to
risk of bias were assessed in each
included trial since there is evidence
that these issues are associated with
biased estimates of treatment effect:
(1) random sequence generation; (2)
allocation concealment; (3) blinding of
participants and personnel; (4) blind-
ing of outcome assessment; (5)
incomplete outcome data; (6) selective
reporting; and (7) other bias. Review
authors’ judgments were categorized as
low risk, high risk, or unclear risk of
bias.11 Risk of bias was assessed by 2
investigators (A.S., G.S.). Disagree-
ments were resolved by consensus with
a third reviewer (V.B.).
The primary outcome was PTB <37
weeks. Secondary outcomes included
PTB <34 weeks, gestational age at de-
livery, latency, birthweight, neonatal
death, admission to neonatal intensive
care unit, neonatal respiratory distress
syndrome, bronchopulmonary dysplasia,
intraventricular hemorrhage, necro-
tizing enterocolitis, and neonatal sepsis.
We performed a subgroup analysis byOCTOBER 2015examining only those trials that included
a placebo, and examined the trials by the
dose of progesterone.
Data analysis
The data analysis was completed inde-
pendently by authors (G.S., A.S., V.B.)
using Review Manager 5.3 (The Nordic
Cochrane Center, Cochrane Collabora-
tion, 2014, Copenhagen, Denmark). The
completed analyses were then compared,
and any difference was resolved with re-
view of the entire data and independent
analysis. Statistical heterogeneity between
studies was assessed using the Cochrane
Q statistic and I2 statistics of Higgins
et al.11 In case of statistical signiﬁcant
heterogeneity (P value of the Cochrane Q
statistic< .1) the random effectsmodel of
DerSimonian and Laird was used to
obtain the pooled relative risks (RRs)
estimate, otherwise a ﬁxed effect models
was planned.11 The summary measures
were reported as RRs, with 95% conﬁ-
dence interval (CI).11 P value < .05 was
considered statistically signiﬁcant.
Results
Study selection and study
characteristics
Figure 1 shows the ﬂow diagram of in-
formation through the different phases
of the review. In all, 21 trials on pro-
gesterone as tocolytic were identi-
ﬁed.8,12-31 Eleven trials were identiﬁed
that evaluated the effect of progesterone
for maintenance tocolysis after PTL.21-31
Six of them were excluded: 4 were
excluded because 17P was evaluated28-31;
1 was excluded because women with
PPROM were evaluated22; and 1 was
excluded because oral progesterone was
evaluated.21 Five trials that met inclusion
criteria for this metaanalysis were
analyzed.23-27
Descriptive data for each trial are
presented in Table 1. A total of 441
singleton gestations with arrested PTL
were included. Most studies used 200mg
of vaginal progesterone daily. Three of 5
used no treatment as control.23,25,27
Three studies deﬁned PTL as the pres-
ence of at least 6 contractions in 30
minutes accompanied by cervical
changes23-25; 1 deﬁned it as the presence
of at least 4 contractions per 20 minutes,
TABLE 1
Descriptive data for each trial
Variable
Borna and
Sahabi,23 2008 Sharami et al,24 2010 Arikan et al,25 2011 Lotfalizadeh et al,27 2013 Areia et al,26 2013 Total
Study location Iran Iran Turkey Iran Portugal e
No. of patients
eprogesterone
vs control
70 (37 vs 33) 163 (80 vs 83) 83 (43 vs 40) 73 (37 vs 36) 52 (26 vs 26) 441 (223 vs 218)
Daily dose, mg 400 200 200 400 200 e
Control No treatment Placebo No treatment No treatment Placebo e
Primary tocolytic
agent
Magnesium sulfate Magnesium sulfate Ritodrine Magnesium sulfate
or nifedipine
Atosiban e
GA at
randomization, wka
240e346 280e366 240e346 260e366 240e346 e
Mean GA at
randomization, wk
31/32 33/34 32/32 34/33 28/29 Mean difference e0.37 d
(95% CI, e1.17 to 0.44)
Definition of PTL At least 6 contractions
in 30 min accompanied
by cervical changes
At least 6 contractions
in 30 min accompanied
by cervical changes
At least 6 contractions
in 30 min accompanied
by cervical changes
At least 4 contractions
per 20 min accompanied
by 2-cm dilatation
At least 4 contractions
per 20 min accompanied
by cervical length <25 mm
Prior PTB
eprogesterone
vs control, n/N (%)
5/37 (13.5%)
vs 4/33 (12.1%)
1/80 (1.3%)
vs 3/83 (3.6%)
4/43 (9.3%)
vs 3/40 (7.5%)
N/R 9/26 (34.6%)
vs 9/26 (34.6%)
28/186 (15.0%)
vs 19/182 (10.4%)
P ¼ .19
Study primary
outcomes
Latency period,
recurrent PTL
Latency period,
PTB <37 wk,
PTB <34 wk
Latency period, GA at
delivery, PTB <37 wk
Rate of recurrent PTL Latency period e
CI, confidence interval; GA, gestational age; N/R, not reported; PTB, preterm birth; PTL, preterm labor.
a Data presented in range.
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FIGURE 2
Assessment of risk of bias
A, Summary of low (þ), high (e), and unclear (?) risk of bias for each trial. B, Risk of bias graph presented as percentages across all included studies.
Areia 201326; Arikan 201125; Borna 200823; Lotfalizadeh 201327; Sharami 2010.24
Suhag. Vaginal progesterone for maintenance tocolysis. Am J Obstet Gynecol 2015.
Systematic Reviews Obstetrics ajog.orgaccompanied by 2-cm dilatation27; and 1
deﬁned it as uterine contractions at least
4 per 20 minutes accompanied by cer-
vical length <25 mm.26
The quality of randomized controlled
trials (RCTs) included in our meta-
analysis was assessed by the Cochrane
Collaboration’s tool11 (Figure 2). All
studies but one27 had adequate random
sequence generation and allocation
concealment. One study was double
blind.24 Figure 3 shows the funnel plot
for assessing publication bias for PTB
<37 weeks. Potential publication bias
was assessed by visual inspection of the
funnel plot, and the symmetric plot
suggested no publication bias.
Of the 441 singleton gestations
included in the 5 trials,23-27 223 (50.5%)
were randomized to vaginal progester-
one, and 218 (49.5%) to control.
Regarding important baseline charac-
teristics of the populations in the orig-
inal trials, 4 RCTs reported data about
prior PTB (Table 1),23-26 and 1 about482 American Journal of Obstetrics& Gynecologycervical length.26 No differences in
baseline characteristics were found be-
tween the progesterone and control
groups in any study. The statistical het-
erogeneity between the studies was very
low, with no inconsistency in the RR
estimates (I2 ¼ 0%). However, given the
clinical heterogeneity (eg, dose of pro-
gesterone, inclusion criteria), a random
effect model was used to assessed the
primary outcome.
Synthesis of results
Women with a singleton gestation who
received vaginal progesterone mainte-
nance tocolysis for arrested PTL had a
signiﬁcantly lower rate of PTB <37
weeks (42% vs 58%; RR, 0.71; 95% CI,
0.57e0.90; 3 trials, 298 women)
(Figure 4).
Women who received vaginal proges-
terone also had signiﬁcantly longer la-
tency (mean difference 13.80 days; 95%
CI, 3.97e23.63; 4 trials, 368 women)
(Figure 5), later gestational age atOCTOBER 2015delivery (mean difference 1.29 weeks;
95% CI, 0.43e2.15; 4 trials, 368 women)
(Figure 6), and lower rate of recurrent
PTL (24% vs 46%; RR, 0.51; 95% CI,
0.31e0.84; 2 trials, 122 women).
Regarding neonatal outcome we found
no differences between progesterone
and control group except for the rate of
neonatal sepsis, which was lower in
the progesterone group compared to
control (2% vs 7%; RR, 0.34; 95% CI,
0.12e0.98; 4 trials, 368 women)
(Table 2). No data about broncho-
pulmonary dysplasia were reported in
any of the trials.
In the subgroup analysis of those trials
that included placebo as control, we
found that vaginal progesterone was
associated with a signiﬁcantly lower risk
of PTB <37 weeks compared to control
(39.6% vs 53.2%; RR, 0.58; 95% CI,
0.34e0.99). Due to limited data, analysis
of the primary outcome in the subgroup
analysis examining by dose of proges-
terone was not feasible.
FIGURE 3
Funnel plot for assessing publication bias
RR, relative risk.
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Main ﬁndings
This metaanalysis of pooled data of 5
RCTs evaluating vaginal progesterone
treatment for maintenance tocolysis af-
ter arrested PTL shows that maintenance
tocolysis with vaginal progesterone is
associated with prevention of PTB
compared to controls (either placebo or
no treatment). Women who received
vaginal progesterone delivered >1 week
later and had a longer latency from
randomization to delivery. Furthermore,
the incidence of recurrent PTLwas noted
to be signiﬁcantly lower in women ran-
domized to vaginal progesterone as
compared to control group, and the rate
of neonatal sepsis was lower.
Discussion and comparison with
existing literature
PTL commonly precedes PTB. Tocolytics
are often used for short-term prol-
ongation of pregnancy, to allow the
obstetrician to administer antenatal cor-
ticosteroids, and magnesium sulfate for
neuroprotection, and to permit transport
of patients to centers with appropriate
level neonatal intensive care units.1 After
successful primary tocolysis, several
maintenance tocolysis agents have been
studied, but none so far have been asso-
ciated with beneﬁts.1 Compared to pla-
cebo, maintenance tocolysis with oral
betamimetics,32 terbutaline pump,33 cal-
cium channel blockers,34-36 cyclo-
oxygenase-2 inhibitors,37-39 magnesium
sulfate,40 oxytocin receptor antagonist41FIGURE 4
Forest plot for preterm birth <37 we
Sharami 201024; Arikan 201125; Areia 2013.26
CI, confidence interval; M-H, Mantel-Haenszel; PTB, preterm birth.
Suhag. Vaginal progesterone for maintenance tocolysis. Am J O(atosiban), or 17P42 have not been asso-
ciated with prevention of PTB or
improvement in neonatal outcomes.
Maintenance tocolysis with progesterone
has been studied in randomized trials, but
so far no clinically useful metaanalysis of
these data has been published, guidelines
have not commented on its use,1 and this
intervention is not routinely discussed or
used in clinical practice.
Only one other metaanalysis evalu-
ated use of progesterone for treatment
of PTL.43 The Cochrane Review oneks
bstet Gynecol 2015.
OCTOBER 2015 Amprogestational agents for treating
threatened or established PTL included
a subgroup analysis of progesterone for
maintenance tocolysis in women with
both arrested PTL and PPROM
together. Moreover, their analysis com-
bined 3 formulations of progesterone
(17P, natural or vaginal progesterone,
and oral progesterone) together.
Including PTL and PPROM together, as
well as different formulations of pro-
gesterone, makes clinical use of these
data limited.erican Journal of Obstetrics& Gynecology 483
FIGURE 5
Forest plot for latency
Areia 201326; Arikan 201125; Borna 200823; Sharami 2010.24
CI, confidence interval; df, degree of freedom; IV, independent variable; SD, standard error.
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Systematic Reviews Obstetrics ajog.orgStrengths and limitations
One of the strengths of our study is the
inclusion of only randomized trials on
vaginal progesterone maintenance
tocolysis in women with arrested PTL in
the only reported metaanalysis speciﬁc
to this topic. Included trials uniformly
deﬁned PTL as preterm contractions
with cervical change. The pooled data
represent a relatively large group of pa-
tients treated with vaginal progesterone
maintenance tocolysis, compared to no
treatment, or placebo. Most studies had
low risk of bias by Cochrane Collabora-
tion’s tool.10 Most trials assessed latency
and some neonatal outcomes. Although
the risk for PTB might have been
different in the trials, 4 of 5 trials (except
Lotfalizadeh et al27) did report if study
subjects had prior PTB or had other risk
factors for PTB.23-26FIGURE 6
Forest plot preterm birth for gestatio
Areia 201326; Arikan 201125; Borna 200823; Sharami 201024.
CI, confidence interval; df, degree of freedom; IV, independent varia
Suhag. Vaginal progesterone for maintenance tocolysis. Am J O
484 American Journal of Obstetrics& GynecologyLimitations of our study are those
inherent to any other metaanalysis. Pri-
mary tocolysis regimen was somewhat
different in the included trials. The
dosage of administration of vaginal
progesterone was different in various
trials (200 mg in 3 trials, 400 mg in 2
trials). Only 2 of the 5 trials included the
sample size calculation23,26; both of these
studies were underpowered, however the
authors were able to show longer latency
in the vaginal progesterone group.23,26
Other shortcomings of our meta-
analysis are that only 2 trials of 5 had as
primary outcome PTB <37 weeks,24,25
and the limited information about
neonatal outcome. No long-term out-
comes were reported in any of the trials.
Given the lack of blinding in some trials,
there is a signiﬁcant potential for bias
especially for some of the secondarynal age at delivery
ble; SD, standard error.
bstet Gynecol 2015.
OCTOBER 2015outcomes. Moreover, none of these trials
were from the United States and so
applicability to the US population may
be limited. One trial reported very
limited data on obstetric and perinatal
outcomes.27 While all authors were
contacted for missing data, we received
additional data only from 1 author.26
Conclusions and implications
In this metaanalysis of the pertinent
randomized trials, maintenance tocol-
ysis with vaginal progesterone after
arrested PTL in singleton gestations was
associated with signiﬁcant 29% preven-
tion of PTB <37 weeks, signiﬁcant pro-
longation of pregnancy by >8 days,
signiﬁcant 49% lower rate of recurrent
PTL, and signiﬁcant 66% decrease in
neonatal sepsis. However, given the lack
of blinding in some trials and the
TABLE 2
Primary and secondary outcomes
Variable
Borna and
Sahabi,23 2008
Sharami
et al,24 2010
Arikan
et al,25 2011
Lotfalizadeh
et al,27 2013
Areia
et al,26 2013 Total RR (95% CI)
No. of patients 70 (37 vs 33) 163 (80 vs 83) 83 (43 vs 40) 73 (37 vs 36) 52 (26 vs 26) 441 (223/218) e
PTB <37 wka N/A 33/80 (41%)
vs 45/83 (54%)
20/43 (47%)
vs 28/40 (70%)
N/A 9/26 (35%)
vs 13/26 (50%)
62/149 (42%)
vs 86/149 (58%)
0.71 (0.57e0.90)b
PTB <34 wka N/A 8/80 (10%)
vs 9/83 (11%)
N/A N/A 3/26 (12%)
vs 6/26 (23%)
11/106 (10%)
vs 15/109 (14%)
0.75 (0.36e1.57)
Recurrent PTLa 13/37 (35%)
vs 19/33 (58%)
N/A N/A N/A 2/26 (8%)
vs 8/26 (31%)
15/63 (24%)
vs 27/59 (46%)
0.51 (0.31e0.84)b
Mean GA
delivery, wk
37 vs 35 37 vs 36 36 vs 35 N/A 38 vs 37 e Mean difference
1.29 wk (0.43e2.15)b
Mean latency, d 36 vs 24 24 vs 17 32 vs 21 N/A 63 vs 39 e Mean difference 13.80 d
(3.97e23.63)b
Mean
birthweight, g
3101 vs 2609 2997 vs 3025 2983 vs 2585 N/A 2547 vs 2628 e Mean difference 194 g
(e100.01 to 488.32)
Neonatal deatha N/A 1/80 (1%)
vs 6/83 (7%)
0/43 vs 1/40 (3%) N/A 2/26 (8%)
vs 2/26 (8%)
3/149 (2%)
vs 9/149 (6%)
0.43 (0.12e1.54)
Admission
in NICUa
9/37 (24%)
vs 13/33 (39%)
3/80 (4%)
vs 2/83 (2%)
3/43 (7%)
vs 3/40 (8%)
10/37 (27%)
vs 14/36 (39%)
5/26 (19%)
vs 7/26 (27%)
30/223 (13%)
vs 39/218 (18%)
0.72 (0.47e1.08)
RDSa 4/37 (11%)
vs 12/33 (36%)
7/80 (9%)
vs 10/83 (12%)
1/43 (2%)
vs 1/40 (3%)
N/A 2/26 (8%)
vs 2/26 (8%)
14/186 (8%)
vs 25/182 (14%)
0.54 (0.30e1.00)
IVHa 0/37 vs 0/33 N/A 0/43 vs 0/40 N/A 0/26 vs 0/26 0/106 (0%)
vs 0/99 (0%)
N/E
NECa 0/37 vs 0/33 N/A 0/43 vs 0/40 N/A 0/26 vs 0/26 0/106 (0%)
vs 0/99 (0%)
N/E
Sepsisa 2/37 (5%)
vs 6/33 (18%)
0/80 vs 3/83 (4%) 2/43 (5%) vs 2/40 (5%) N/A 0/26 vs 1/26 (4%) 4/186 (2%)
vs 11/156 (7%)
0.34 (0.12e0.98)b
CI, confidence interval; GA, gestational age; IVH, intraventricular hemorrhage; N/A, not available; N/E, not estimable; N/R, not reported; NEC, necrotizing enterocolitis; NICU, neonatal intensive care unit; PTB, preterm birth; PTL, preterm labor; RDS, respiratory
distress syndrome; RR, relative risk.
a Data are presented progesterone, n, vs control, n (percentage); b Statistically significant.
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Systematic Reviews Obstetrics ajog.orggenerally poor quality of the trials, we do
not suggest a change in clinical care of
women with arrested PTL. We suggest
well-designed placebo-controlled ran-
domized trials to conﬁrm the ﬁndings of
our metaanalysis. We observed that with
a of 0.05 and 80% power, a sample size
of 250 women in each group is required
to detect a 29% decrease in PTB. -
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